Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 19/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18583291 | 0.87 | RIPK1 (0.42) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL20676070 | 0.86 | RIPK1 (0.38) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL19222408 | 0.80 | RIPK1 (0.39) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL21191525 | 0.71 | RIPK1 (0.36) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL21755111 | 0.69 | RIPK1 (0.53) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL22877589 | 0.65 | CCNT1 (0.34) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL21191614 | 0.64 | RIPK1 (0.34) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1780991 | 0.62 | CYP19A1 (0.66) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1778505 | 0.62 | RIPK1 (0.74) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL12606340 | 0.62 | CCNB2 (0.63) | RIPK1CCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752598-B2 | Aryldiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-9765035-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9604930-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752598-B2 | Aryldiazepine derivatives as RSV inhibitors | AHR, FURIN, CYP3A5 | RIPK1 2685/4885CCNB2 2093/4885CDK1 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.